Abstract
Background Tau PET imaging enables prospective longitudinal observation of the rate and location of tau accumulation in Alzheimer’s disease (AD). 18F-MK6240 is a newer, high affinity tracer for the paired helical filaments of tau in AD. It is widely used in clinical trials, despite sparse longitudinal natural history data. We aimed to evaluate the impact of disease stage, and two reference regions on the magnitude and effect size of regional change.
Methods One hundred and fifty-eight participants: 83 cognitively unimpaired (CU) Aβ-, 37 CU Aβ+, 19 mild cognitively impaired (MCI) Aβ+ and 19 AD Aβ+ had annual 18F-MK6240 PET for one or two years (mean 1.6 years). Standardized uptake value ratios (SUVR) were generated for three in-house composite ROI: mesial temporal (Me), temporoparietal (Te), and rest of neocortex (R), and a Free-Surfer derived meta-temporal (MT) ROI. Two reference regions were examined: cerebellar cortex (SUVRCb) and eroded subcortical white matter (SUVRWM).
Results Low rates of accumulation were seen in CU Aβ-, predominantly in the mesial temporal lobe (MTL). In CU Aβ+, increase was greatest in the MTL, particularly the amygdala. In MCI Aβ+, a similar increase was seen in MTL, but also globally in the cortex. In AD Aβ+, greatest increase was in temporoparietal and frontal regions, with a decrease in the MTL. In CU and MCI increases were greater using SUVRWM. In AD, the SUVRCb showed marginally greater increase. Interpolation of the data suggests it takes approximately two decades to accumulate tau to the typical levels found in AD, similar to the rates of accumulation of Aβ plaques.
Conclusions The rate of tau accumulation varies according to brain region and baseline disease stage, confirming previous reports. The PET measured change is greater, with fewer outliers, using an eroded white matter reference region, except in AD. While the eroded subcortical white matter reference may be preferred for trials in preclinical AD, the cerebellar cortex would be preferred for trials in symptomatic AD.
Trial registration Not applicable.
Competing Interest Statement
CCR was the recipient of a research grant from Cerveau, who supplied the MK6240 tau tracer precursor for research use. CCR has received grants from Cerveau Technologies (institution), Eisai (institution) and Biogen (institution). CCR has received consulting fees from Nutricia (speaker fee), Prothena and Biogen (for preparation of educational material). CCR has participated on a data safety board/ advisory board for Cerveau Technologies (unpaid). VLV has received consulting fees from IXICO, Eli Lilly, Life molecular imaging and Hospicom and has received payment/ honoraria from ACE Barcelona. NK, VD, PB, JR, LW, CF, JF and CLM do not report any disclosures.
Funding Statement
This work was supported by the National Health and Medical Research Council (NHMRC) (grant numbers APP1132604, APP1140853). NK was supported by a cofunded PhD scholarship from Australian Rotary Health/ Estate of Bartolina Peluso.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Austin Health gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Abbreviations
- CU
- cognitively unimpaired
- Me
- mesial temporal composite
- MT
- meta-temporal composite
- Te
- temporoparietal composite
- R
- rest of neocortex composite
- SUVR
- standardized uptake value ratio
- SUVRCb
- standardized uptake value ratio normalized to a cerebellar cortex reference region
- SUVRWM
- standardized uptake value ratio normalized to an eroded subcortical white matter reference region
- MTL
- mesial temporal lobe
- AIBL
- Australian Imaging Biomarkers and Lifestyle Study of Ageing
